Jerini and Shire have reviewed Jerini's assets and have elected to divest Jerini Ophthalmic, JPT Peptide Technologies and Jerini's pre-clinical projects. Jerini will explore options to maximize benefits for for the company from the sale of these assets. The companies will now focus on icatibant (Firazyr), a treatment for hereditary angioedema. The drug has received marketing authorization in the EU and will be launched this year, but it ran into some trouble with the FDA, which refused to approved the drug. Shire purchased Jerini for $521 million in June.
- see Jerini's release